Agenus posts corporate presentation spotlighting botensilimab-balstilimab neoadjuvant strategy in MSS colon cancer

• Agenus outlined a registrational Phase 3 “ROBBIN” trial of botensilimab with balstilimab in neoadjuvant MSS colon cancer; n=850; primary endpoint event-free survival.
• Two neoadjuvant investigator studies (NEST, UNICORN) in 52 patients showed about 30% pCR in MSS (n=38) with 100% EFS at 9-18 months.
• Trial start targeted for first patient in by Q1 2027; interim pathologic response readout expected in 2H 2027; interim EFS analysis in 2H 2029.
• PIPE financing totals USD 340 million including warrants; upfront USD 85 million at USD 3.69; designed to fund operations through end-2031.
• Implied issuance of 78 million new shares across upfront and warrants; 42,680,014 shares outstanding pre-transaction as of July 10, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.